Dr. Westhoff Mike-andrew

Dr. Westhoff Mike-andrew

Deputy head of research group

Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm
Eythstrasse 24, Ulm, Germany, D-89075

plus Speciality

CANCER

Biography:

2003-2010: Post-doctorate AG Fulda research group, University Medical Center Ulm, Germany 1999-2002: Ph.D. in molecular pathology and cancer sciences University of Glasgow, G.B. Thesis topic: Control of Focal Adhesion Kinase By Src-Mediated Phosphorylation 1995-1999: B.Sc. (Hon.) Genetics Abschluss University of Glasgow, G.B. First class degree

Academic positions:

Deputy head of the Apoptosis and Cancer Therapy research group, University Medical Center Ulm, Germany

Research interests:

Neurooncology; Glioblastoma; Combination therapy; Invasion and Motility

Any other information:

Publications: 1. Karpel-Massler G, Westhoff MA, Kast RE, Dwucet A, Nonnenmacher L, Debatin KM, et al (2014). Artesunate Enhances The Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell lines. Anzi-cancer agents Med Chem 14(2). 2. Westhoff MA, Faham, N, Marx D, Nonnenmacher L, Jennewein C, Enzenm├╝ller S, et al (2013). Sequential dosing in chemosensitization: Targeting the PI3K/Akt/mTOR pathway in Neuroblastoma. PLOS One 8(12). 3. Westhoff MA, Zhou S, Nonnenmacher L, Karpel-Massler G, Jennewein C, Schneider M et al (2013). Inhibition of NF-kappaB Signaling Ablates the Invasive Phenotype of Glioblastoma. Mol Cancer Res. 4. Lewerenz J, Baxter P, Kassubek R, Albrecht P, Van Liefferinge J, Westhoff MA et al (2013). Phosphoinositide 3-kinases upregulate system xc- via eIF2alpha and ATF4 - a pathway active in glioblastomas and epilepsy. Antioxid Redox Signal. 5. Herrmann MD, Lennerz JK, Bullinger L, Bartholomae S, Holzmann K, Westhoff MA et al (2013). Transitory dasatinib-resistant states in KITmut t(8;21) acute myeloid leukemia cells correlate with altered KIT expression. Exp Hematol. 6. Karpel-Massler G, Westhoff MA, Zhou S, Nonnenmacher L, Dwucet A, Kast RE et al (2013). Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells. Mol Cancer Ther 12: 1783-95. 7. Keuper M, Wernstedt Asterholm I, Scherer PE, Westhoff MA, Moller P, Debatin KM et al (2013). TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma. Cell Death Dis 4: e474. 8. Fabricius D, Nussbaum B, Busch D, Panitz V, Mandel B, Vollmer A et al (2013). Antiviral vaccines license T cell responses by suppressing granzyme B levels in human plasmacytoid dendritic cells. J Immunol 191: 1144-53. 9. Merkur N, Westhoff MA, Karpel-Massler G, Halatsch ME (2012). Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment. Current Signal Transduction Therapy 7: 3-13. 10. Karpel-Massler G, Westhoff MA, Kast RE, Wirtz CR, Halatsch ME (2011). Erlotinib in Glioblastoma - Lost in Translation? Anticancer Agents Med Chem. 11. Westhoff MA, Fulda S (2009). Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat 12: 127-36. 12. Westhoff MA, Kandenwein JA, Karl S, Vellanki SH, Braun V, Eramo A et al (2009). The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene 28: 3586-96. 13. Strauss G, Westhoff MA, Fischer-Posovszky P, Fulda S, Schanbacher M, Eckhoff SM et al (2008). 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ 15: 332-43. 14. Westhoff MA, Zhou S, Bachem MG, Debatin KM, Fulda S (2008). Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 27: 5169-81. 15. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S (2008). Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68: 6271-80. 16. La Ferla-Bruhl K, Westhoff MA, Karl S, Kasperczyk H, Zwacka RM, Debatin KM et al (2007). NF-kappaB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition. Oncogene 26: 571-82. 17. Corbacioglu S, Kilic M, Westhoff MA, Reinhardt D, Fulda S, Debatin KM (2006). Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 108: 3504-13. 18. Kasperczyk H, La Ferla-Bruhl K, Westhoff MA, Behrend L, Zwacka RM, Debatin KM et al (2005). Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 24: 6945-56. 19. Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM, Fulda S (2005). Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 65: 10502-13. 20. Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO (2004). SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol 24: 8113-33. 21. Carragher NO, Westhoff MA, Fincham VJ, Schaller MD, Frame MC (2003). A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src. Curr Biol 13: 1442-50. 22. Carragher NO, Westhoff MA, Riley D, Potter DA, Dutt P, Elce JS et al (2002). v-Src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation. Mol Cell Biol 22: 257-69. 23. Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG et al (2002). Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 4: 632-8.

What I think of the idea behind WebmedCentral and WebmedCentral plus:

An excellent idea to help the community to interact more directly